FX-909
Flare Therapeutics
['urothelial']
#flaretherapeutics presents first preclinical data on lead asset #fx909, a novel #smallmolecule #pparginhibitor to potentially treat #urothelialcancer, at the #aacr23 
Follow top-line development in the oncology commercial domain through our award winning intelligence service, 1stOncology.